Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms

[1]  R. Webby,et al.  Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents , 2022, Nature.

[2]  Christopher J. L. Murray,et al.  Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. , 2022, JAMA.

[3]  Z. Al-Aly,et al.  Long-term neurologic outcomes of COVID-19 , 2022, Nature Medicine.

[4]  S. Tavazoie,et al.  Common human genetic variants of APOE impact murine COVID-19 mortality , 2022, Nature.

[5]  F. Chen,et al.  The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms , 2022, Translational neurodegeneration.

[6]  Quanxin Long,et al.  APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients , 2022, Signal Transduction and Targeted Therapy.

[7]  C. Jack,et al.  The AT(N) system for describing biological changes in Alzheimer's disease: a plain language summary. , 2022, Neurodegenerative Disease Management.

[8]  J. Gladman,et al.  Impact of COVID-19 lockdown on physical exercise among participants receiving the Promoting Activity, Independence and Stability in Early Dementia (PrAISED) intervention: a repeated measure study , 2022, BMC Geriatrics.

[9]  P. Cortelli,et al.  Risk of SARS‐CoV‐2 infection, hospitalization, and death for COVID‐19 in people with Parkinson disease or parkinsonism over a 15‐month period: A cohort study , 2022, European journal of neurology.

[10]  N. Pai,et al.  The physical and mental health consequences of social isolation and loneliness in the context of COVID-19 , 2022, Current opinion in psychiatry.

[11]  E. Rolls,et al.  Associations of Social Isolation and Loneliness With Later Dementia , 2022, Neurology.

[12]  M. Rizzone,et al.  SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review , 2022, Neurological Sciences.

[13]  S. Barbieri,et al.  The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey , 2022, Healthcare.

[14]  K. Vadikolias,et al.  Cognitive, Functional, and Emotional Changes During the COVID-19 Pandemic in Greek Patients with Neurocognitive Disorders. , 2022, Journal of Alzheimer's disease : JAD.

[15]  M. Diamond,et al.  Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 , 2022, Nature.

[16]  C. Popescu,et al.  Parkinson’s Disease and SARS-CoV-2 Infection: Particularities of Molecular and Cellular Mechanisms Regarding Pathogenesis and Treatment , 2022, Biomedicines.

[17]  U. Fedeli,et al.  Parkinson’s disease related mortality: Long-term trends and impact of COVID-19 pandemic waves , 2022, Parkinsonism & Related Disorders.

[18]  J. Morowitz,et al.  Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review , 2022, Brain sciences.

[19]  D. Kaelber,et al.  COVID‐19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021 , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[20]  R. Sánchez-Valle,et al.  CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome , 2022, Frontiers in Immunology.

[21]  L. Kazis,et al.  Clinical outcomes of COVID‐19 infection among patients with Alzheimer's disease or mild cognitive impairment , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[22]  C. Steves,et al.  Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.

[23]  A. Kaushik,et al.  Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk? , 2022, Expert review of neurotherapeutics.

[24]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[25]  M. Diamond,et al.  Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2 , 2022, Research square.

[26]  Y. Pijnenburg,et al.  The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study , 2022, Scientific Reports.

[27]  S. Reiken,et al.  Alzheimer's‐like signaling in brains of COVID‐19 patients , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[28]  B. Fougère,et al.  The Role of Telemedicine in the Management of the Behavioral and Psychological Symptoms of Dementia: A Systematic Review. , 2022, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[29]  Frances E. Muldoon,et al.  Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.

[30]  E. Keller,et al.  Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients , 2022, Journal of neuroinflammation.

[31]  S. Galetta,et al.  Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[32]  R. Mezzenga,et al.  Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19 , 2022, Nature Communications.

[33]  A. Rosenzweig,et al.  Using Telemedicine to Assess and Manage Psychosis in Neurodegenerative Diseases in Long-Term Care , 2022, Journal of the American Medical Directors Association.

[34]  S. Lipton,et al.  Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer’s Disease, Parkinson’s Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome , 2022, Antioxidants.

[35]  K. To,et al.  Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron , 2021, Nature.

[36]  F. Pasquier,et al.  Telemedicine in French Memory Clinics During the COVID-19 Pandemic. , 2021, Journal of Alzheimer's disease : JAD.

[37]  A. T. Yu,et al.  Long-term Neuropsychiatric Complications and 18F-FDG-PET Hypometabolism in the Brain From Prolonged Infection of COVID-19 , 2021, Alzheimer disease and associated disorders.

[38]  H. Sekhon,et al.  A Systematic Review of Telemedicine for Older Adults With Dementia During COVID-19: An Alternative to In-person Health Services? , 2021, Frontiers in Neurology.

[39]  M. Noroozian,et al.  Lessons from COVID‐19 pandemic: Clinical experiences on telemedicine in patients with dementia in Iran , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[40]  K. Kaila,et al.  APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study , 2021, Acta neuropathologica communications.

[41]  F. Wegner,et al.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson’s Disease? , 2021, Brain sciences.

[42]  A. Forster,et al.  Information provision for stroke survivors and their carers. , 2021, The Cochrane database of systematic reviews.

[43]  F. Barkhof,et al.  Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease , 2021, JAMA neurology.

[44]  R. Cantello,et al.  Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson’s disease patient , 2021, Neurological Sciences.

[45]  S. Ghozy,et al.  Vitamin D and its' role in Parkinson's disease patients with SARS-CoV-2 infection. A review article , 2021, Interdisciplinary Neurosurgery.

[46]  M. Kivipelto,et al.  Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions , 2021, Journal of Neurology.

[47]  N. Xiong,et al.  Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease , 2021, Frontiers in Immunology.

[48]  Sevinc Bayram,et al.  A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene , 2021, Brain : a journal of neurology.

[49]  J. Al-Hashel,et al.  Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis , 2021, Frontiers in Neurology.

[50]  S. Bhatia,et al.  Linking COVID-19 and Parkinson's disease: Targeting the role of Vitamin-D , 2021, Biochemical and Biophysical Research Communications.

[51]  M. Morris,et al.  Online Dance Therapy for People With Parkinson’s Disease: Feasibility and Impact on Consumer Engagement , 2021, Neurorehabilitation and neural repair.

[52]  Thalia Shoshana Field,et al.  Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. , 2021, JAMA neurology.

[53]  C. Hertogh,et al.  Dementia and Parkinson’s Disease: Risk Factors for 30-Day Mortality in Nursing Home Residents with COVID-19 , 2021, Journal of Alzheimer's disease : JAD.

[54]  M. Heneka,et al.  Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus , 2021, Nature Reviews Neurology.

[55]  I. Burger,et al.  Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination , 2021, SN Comprehensive Clinical Medicine.

[56]  Ping Wu,et al.  Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action , 2021, EClinicalMedicine.

[57]  O. Monchi,et al.  Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience , 2021, Parkinsonism & Related Disorders.

[58]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[59]  G. Ambler,et al.  Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis , 2021, The New England journal of medicine.

[60]  M. T. Pellecchia,et al.  Severe Dyskinesia After Administration of SARS‐CoV2 mRNA Vaccine in Parkinson's Disease , 2021, Movement disorders : official journal of the Movement Disorder Society.

[61]  D. Waldvogel,et al.  Worsened Parkinson's Disease Progression: Impact of the COVID-19 Pandemic. , 2021, Journal of Parkinson's disease.

[62]  A. Pisani,et al.  Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: A critical systematic review , 2021, European journal of neurology.

[63]  Yun Wang,et al.  The Effects of Aβ1-42 Binding to the SARS-CoV-2 Spike Protein S1 Subunit and Angiotensin-Converting Enzyme 2 , 2021, International journal of molecular sciences.

[64]  S. Sinha,et al.  Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy , 2021, Journal of movement disorders.

[65]  Yong Ji,et al.  The Impact of the COVID-19 Pandemic and Lockdown on Mild Cognitive Impairment, Alzheimer's Disease and Dementia With Lewy Bodies in China: A 1-Year Follow-Up Study , 2021, Frontiers in Psychiatry.

[66]  B. Strooper,et al.  Cellular senescence at the crossroads of inflammation and Alzheimer's disease , 2021, Trends in Neurosciences.

[67]  Kevin Luke,et al.  Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[68]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2021, EClinicalMedicine.

[69]  A. Dmytriw,et al.  The impact of Parkinson's disease on manifestations and outcomes of Covid‐19 patients: A systematic review and meta‐analysis , 2021, Reviews in medical virology.

[70]  Yong Ji,et al.  The Impact of the COVID-19 Pandemic on Alzheimer's Disease and Other Dementias , 2021, Frontiers in Psychiatry.

[71]  M. Naharci,et al.  Delirium in a patient with Alzheimer's dementia following COVID‐19 vaccination , 2021, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[72]  C. Conte.  Possible Link between SARS-CoV-2 Infection and Parkinson’s Disease: The Role of Toll-Like Receptor 4 , 2021, International journal of molecular sciences.

[73]  I. Cobos,et al.  Dysregulation of brain and choroid plexus cell types in severe COVID-19 , 2021, Nature.

[74]  M. Schiller,et al.  Severe COVID-19 in Alzheimer’s disease: APOE4’s fault again? , 2021, Alzheimer's Research & Therapy.

[75]  E. Poliakoff,et al.  Dance at Home for People With Parkinson's During COVID-19 and Beyond: Participation, Perceptions, and Prospects , 2021, Frontiers in Neurology.

[76]  A. Benazzouz,et al.  Covid‐19 Infection and Parkinsonism: Is There a Link? , 2021, Movement disorders : official journal of the Movement Disorder Society.

[77]  D. Chambergo-Michilot,et al.  Factors associated with COVID‐19 in people with Parkinson’s disease: a systematic review and meta‐analysis , 2021, European journal of neurology.

[78]  A. Galanopoulou,et al.  Outcome of Hospitalized Parkinson's Disease Patients with and without COVID‐19 , 2021, Movement disorders clinical practice.

[79]  R. Gold,et al.  Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany , 2021, Movement disorders : official journal of the Movement Disorder Society.

[80]  Jialin C. Zheng,et al.  COVID-19 and Alzheimer’s disease: how one crisis worsens the other , 2021, Translational Neurodegeneration.

[81]  A. Kurniawan,et al.  Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression , 2021, Parkinsonism & Related Disorders.

[82]  Peter M Gliatto,et al.  Barriers to telehealth access among homebound older adults , 2021, Journal of the American Geriatrics Society.

[83]  C. Blum,et al.  Interactions between SARS-CoV-2 N-Protein and α-Synuclein Accelerate Amyloid Formation , 2021, bioRxiv.

[84]  T. Naicker,et al.  Insulin resistance in COVID-19 and diabetes , 2021, Primary Care Diabetes.

[85]  C. Weiller,et al.  Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19 , 2021, Brain : a journal of neurology.

[86]  C. Weiller,et al.  Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients , 2021, The Journal of Nuclear Medicine.

[87]  J. Fedorowski.  Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform? , 2021, Archives of medical science : AMS.

[88]  A. Khandji,et al.  COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital , 2021, medRxiv.

[89]  M. Masellis,et al.  Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond , 2021, Canadian Medical Association Journal.

[90]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[91]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[92]  M. Gurney,et al.  COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[93]  M. Romero-Ramos,et al.  Periphery and brain, innate and adaptive immunity in Parkinson’s disease , 2021, Acta Neuropathologica.

[94]  Pingping Wang,et al.  COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas , 2021, Cell.

[95]  M. Silverman,et al.  Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19 , 2021, Chest.

[96]  B. Harris,et al.  Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer’s Disease , 2021, International journal of molecular sciences.

[97]  B. Bloem,et al.  COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel? , 2021, Journal of Parkinson's disease.

[98]  K. Hoang-Xuan,et al.  The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[99]  Ernesto Estrada.  Cascading from SARS-CoV-2 to Parkinson’s Disease through Protein-Protein Interactions , 2021, Viruses.

[100]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2021, The Journal of experimental medicine.

[101]  M. Aarabi,et al.  Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration , 2021, Molecular Neurobiology.

[102]  Qi Cui,et al.  ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response , 2021, Cell Stem Cell.

[103]  B. Hyman,et al.  APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. , 2021, The Lancet Neurology.

[104]  Rae Woong Park,et al.  Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis , 2020, The Lancet Digital Health.

[105]  J. Obeso,et al.  SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy , 2020, The Lancet Neurology.

[106]  D. Berry,et al.  A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody , 2020, Alzheimer's Research & Therapy.

[107]  J. MacCabe,et al.  Clozapine treatment and risk of COVID-19 infection: retrospective cohort study , 2020, The British Journal of Psychiatry.

[108]  M. Filippi,et al.  The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey , 2021, Frontiers in Aging Neuroscience.

[109]  T. Vecchi,et al.  Cognitive Telerehabilitation for Older Adults With Neurodegenerative Diseases in the COVID-19 Era: A Perspective Study , 2021, Frontiers in Neurology.

[110]  R. Pranata,et al.  Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: A systematic review and meta‐analysis , 2020, Geriatrics & gerontology international.

[111]  H. Ulrich,et al.  Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology , 2020, Molecular Psychiatry.

[112]  N. Rosenthal,et al.  Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19 , 2020, JAMA network open.

[113]  Hao Li,et al.  The Impact of Dementia on the Clinical Outcome of COVID-19: A Systematic Review and Meta-Analysis. , 2020, Journal of Alzheimer's disease : JAD.

[114]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[115]  L. Giménez-Llort,et al.  Impact of Social Isolation on the Behavioral, Functional Profiles, and Hippocampal Atrophy Asymmetry in Dementia in Times of Coronavirus Pandemic (COVID-19): A Translational Neuroscience Approach , 2020, Frontiers in Psychiatry.

[116]  R. M. Manero,et al.  Effects of COVID-19 Pandemic Confinement in Patients With Cognitive Impairment , 2020, Frontiers in Neurology.

[117]  D. Kriebel,et al.  Hypertension, medications, and risk of severe COVID‐19: A Massachusetts community‐based observational study , 2020, Journal of clinical hypertension.

[118]  P. Cortelli,et al.  Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism , 2020, Movement disorders : official journal of the Movement Disorder Society.

[119]  L. Martins,et al.  Alzheimer’s and Parkinson’s Diseases Predict Different COVID-19 Outcomes: A UK Biobank Study , 2020, medRxiv.

[120]  M. Cruz-Ramos,et al.  NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19 , 2020, Frontiers in Immunology.

[121]  V. Devanathan.  Reader response: Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology update , 2020, Neurology.

[122]  Xi Wu,et al.  Management of Parkinson's disease patients after DBS by remote programming: preliminary application of single center during quarantine of 2019-nCoV , 2020, Journal of Neurology.

[123]  I. Parees,et al.  COVID-19 in Parkinson’s disease: what holds the key? , 2020, Journal of Neurology.

[124]  P. Brundin,et al.  Is COVID-19 a Perfect Storm for Parkinson’s Disease? , 2020, Trends in Neurosciences.

[125]  M. Rahman,et al.  Neurobiochemical Cross-talk Between COVID-19 and Alzheimer’s Disease , 2020, Molecular Neurobiology.

[126]  S. Elkabes,et al.  Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases , 2020, Brain, Behavior, and Immunity.

[127]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[128]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[129]  A. G. de la Fuente,et al.  Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe? , 2020, Frontiers in Aging Neuroscience.

[130]  A. Rojas-Fernandez,et al.  The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson's Disease , 2020, Frontiers in Neurology.

[131]  N. Bornstein,et al.  A case of probable Parkinson's disease after SARS-CoV-2 infection , 2020, The Lancet Neurology.

[132]  K. M. de Almondes,et al.  The Influence of Telemedicine Care on the Management of Behavioral and Psychological Symptoms in Dementia (BPSD) Risk Factors Induced or Exacerbated During the COVID-19 Pandemic , 2020, Frontiers in Psychiatry.

[133]  S. Rossi,et al.  Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region , 2020, Journal of Neurology.

[134]  R. Allegri,et al.  COVID-19 Epidemic in Argentina: Worsening of Behavioral Symptoms in Elderly Subjects With Dementia Living in the Community , 2020, Frontiers in Psychiatry.

[135]  D. Cummings,et al.  Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.

[136]  A. Paramasivam,et al.  Repurposing calcium channel blockers as antiviral drugs , 2020, Journal of Cell Communication and Signaling.

[137]  A. Fasano,et al.  Predictors of COVID-19 outcome in Parkinson's disease , 2020, Parkinsonism & Related Disorders.

[138]  Eric E. Smith,et al.  Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[139]  D. Santos-García,et al.  Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients , 2020, Movement disorders : official journal of the Movement Disorder Society.

[140]  B. Yee,et al.  The Protective Impact of Telemedicine on Persons With Dementia and Their Caregivers During the COVID-19 Pandemic , 2020, The American Journal of Geriatric Psychiatry.

[141]  S. Craft,et al.  Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches , 2020, The Lancet Neurology.

[142]  D. Melzer,et al.  Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[143]  C. Tanner,et al.  The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease , 2020, medRxiv.

[144]  Faramarz Ismail-Beigi,et al.  Factors leading to high morbidity and mortality of COVID‐19 in patients with type 2 diabetes , 2020, Journal of diabetes.

[145]  C. C. Danta.  Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection. , 2020, ACS chemical neuroscience.

[146]  Maria Thom,et al.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.

[147]  R. Kenny,et al.  Perspective: Vitamin D deficiency and COVID‐19 severity – plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis , 2020, Journal of internal medicine.

[148]  E. Masliah,et al.  Cellular senescence and Alzheimer disease: the egg and the chicken scenario , 2020, Nature Reviews Neuroscience.

[149]  H. Wood.  New insights into the neurological effects of COVID-19 , 2020, Nature Reviews Neurology.

[150]  I. Trougakos,et al.  Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators , 2020, Redox Biology.

[151]  G. Aranda-Abreu,et al.  Use of amantadine in a patient with SARS‐CoV‐2 , 2020, Journal of medical virology.

[152]  G. Aranda-Abreu,et al.  Amantadine Treatment for People with COVID-19 , 2020, Archives of Medical Research.

[153]  V. Ojetti,et al.  Clinical characteristics and prognostic factors in COVID‐19 patients aged ≥80 years , 2020, Geriatrics & gerontology international.

[154]  G. Chaubey,et al.  Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis , 2020, American journal of physiology. Cell physiology.

[155]  A. Fasano,et al.  COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy , 2020, Movement disorders : official journal of the Movement Disorder Society.

[156]  Asir John Samuel,et al.  E-Rehabilitation: One solution for patients with Parkinson's disease in COVID-19 era , 2020, Parkinsonism & Related Disorders.

[157]  M. Trabucchi,et al.  Clinical Presentation of COVID19 in Dementia Patients , 2020, The journal of nutrition, health & aging.

[158]  C. Caltagirone,et al.  Disability through COVID‐19 pandemic: neurorehabilitation cannot wait , 2020, European journal of neurology.

[159]  Z. Mari,et al.  Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future. , 2020, Journal of Parkinson's disease.

[160]  D. Melzer,et al.  APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort , 2020, medRxiv.

[161]  Antonio Cuesta-Vargas,et al.  Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study , 2020, Journal of medical Internet research.

[162]  P. Cobbold,et al.  Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease , 2020, Brain sciences.

[163]  A. Troxel,et al.  Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.

[164]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[165]  K. Farsalinos,et al.  Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system , 2020, Toxicology Reports.

[166]  M. Polymeropoulos,et al.  Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment , 2020, International Journal of Antimicrobial Agents.

[167]  Konrad Rejdak,et al.  Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment , 2020, Multiple Sclerosis and Related Disorders.

[168]  K. Chaudhuri,et al.  Outcome of Parkinson's Disease Patients Affected by COVID‐19 , 2020, Movement disorders : official journal of the Movement Disorder Society.

[169]  J. Sejvar,et al.  Neurological associations of COVID-19 , 2020, The Lancet Neurology.

[170]  J. Changeux,et al.  A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. , 2020, Comptes rendus biologies.

[171]  M. Steinman,et al.  Meeting the Care Needs of Older Adults Isolated at Home During the COVID-19 Pandemic. , 2020, JAMA internal medicine.

[172]  K. Bhatia,et al.  Movement Disorders in the World of COVID‐19 , 2020, Movement Disorders Clinical Practice.

[173]  A. Kriško,et al.  SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration , 2020, Movement disorders : official journal of the Movement Disorder Society.

[174]  L. French,et al.  The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains , 2020, bioRxiv.

[175]  J. Porta‐Etessam,et al.  Should we expect neurological symptoms in the SARS-CoV-2 epidemic? , 2020, Neurologia.

[176]  K. Bhatia,et al.  Movement Disorders in the World of COVID‐19 , 2020, Movement disorders : official journal of the Movement Disorder Society.

[177]  N. Vaninov.  In the eye of the COVID-19 cytokine storm , 2020, Nature Reviews Immunology.

[178]  S. Nataf.  An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID‐19 , 2020, Journal of medical virology.

[179]  R. Helmich,et al.  The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities , 2020, Journal of Parkinson's disease.

[180]  J. Matías-Guiu,et al.  ¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2? , 2020, Neurología.

[181]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[182]  S. Weidtkamp‐Peters,et al.  Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation , 2020, Proceedings of the National Academy of Sciences.

[183]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[184]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[185]  S. Gauthier,et al.  Remote cognitive and behavioral assessment: Report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID‐19 , 2020, Alzheimer's & dementia.

[186]  R. Franco,et al.  Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra , 2019, Brain, Behavior, and Immunity.

[187]  M. Chumley,et al.  Prolonged isolation stress accelerates the onset of Alzheimer’s disease-related pathology in 5xFAD mice despite running wheels and environmental enrichment , 2019, Behavioural Brain Research.

[188]  T. Oscanoa.  Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis. , 2020, Current Clinical Pharmacology.

[189]  R. Sperling,et al.  Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways , 2019, Nature Reviews Neurology.

[190]  B. Ovbiagele,et al.  Concomitant diabetes or hypertension with metabolic syndrome on the extent of intracranial atherosclerotic stenosis , 2019, Neurological Sciences.

[191]  L. Buée,et al.  NLRP3 inflammasome activation drives tau pathology , 2019, Nature.

[192]  S. Bonasera,et al.  Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-being, and Health Care Use: The Care Ecosystem Randomized Clinical Trial. , 2019, JAMA internal medicine.

[193]  K. Nakajima,et al.  Role of the Immune System in the Development of the Central Nervous System , 2019, Front. Neurosci..

[194]  M. Donath,et al.  Targeting innate immune mediators in type 1 and type 2 diabetes , 2019, Nature Reviews Immunology.

[195]  M. Heneka,et al.  Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome , 2019, The EMBO journal.

[196]  J. Hardy,et al.  Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk , 2019, Brain communications.

[197]  L. Brundin,et al.  Can infections trigger alpha-synucleinopathies? , 2019, Progress in molecular biology and translational science.

[198]  Liang Shen,et al.  Impact of infection on risk of Parkinson’s disease: a quantitative assessment of case-control and cohort studies , 2019, Journal of NeuroVirology.

[199]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[200]  J. Cummings,et al.  ABBY , 2018, Neurology.

[201]  Inhwa Hwang,et al.  MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration , 2018, Cell Death & Differentiation.

[202]  S. Gatzonis,et al.  Parkinson's disease pathogenesis, evolution and alternative pathways: A review. , 2018, Revue neurologique.

[203]  C. Chen,et al.  Angiotensin-converting enzyme 2 regulates mitochondrial function in pancreatic β-cells. , 2018, Biochemical and biophysical research communications.

[204]  S. Lipton,et al.  Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate , 2017, F1000Research.

[205]  M. Andjelkovic,et al.  A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[206]  D. Hoover.  Cholinergic modulation of the immune system presents new approaches for treating inflammation , 2017, Pharmacology & therapeutics.

[207]  Christopher Power,et al.  Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts , 2017, Brain : a journal of neurology.

[208]  Hyun Kim,et al.  Serum tumour necrosis factor‐α and interleukin‐6 levels in Alzheimer's disease and mild cognitive impairment , 2017, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[209]  C. Sankhla,et al.  Oxidative stress and Parkinson's disease , 2017, Neurology India.

[210]  J. Jhoo,et al.  The effect of telemedicine on cognitive decline in patients with dementia , 2017, Journal of telemedicine and telecare.

[211]  Xin Wang,et al.  The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer’s disease: A meta-analysis , 2016, Journal of Clinical Neuroscience.

[212]  J. Hayes,et al.  Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. , 2015, Free radical biology & medicine.

[213]  K. Bhatia,et al.  Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view , 2015, npj Parkinson's Disease.

[214]  E. Liu,et al.  Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[215]  B. Polster,et al.  NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair? , 2014, Free radical biology & medicine.

[216]  H. Sawada,et al.  Delirium and High Fever Are Associated with Subacute Motor Deterioration in Parkinson Disease: A Nested Case-Control Study , 2014, PloS one.

[217]  J. Csernansky,et al.  Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice , 2014, Psychopharmacology.

[218]  O. Hwang.  Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.

[219]  P. Christos,et al.  Clinical Characteristics of Exacerbations in Parkinson Disease , 2012, The neurologist.

[220]  P. Gean,et al.  The Involvement of Cdk5 Activator p35 in Social Isolation-Triggered Onset of Early Alzheimer’s Disease-Related Cognitive Deficit in the Transgenic Mice , 2011, Neuropsychopharmacology.

[221]  J. Kornhuber,et al.  Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system , 2010, Journal of cellular physiology.

[222]  F. Schmidt.  Meta-Analysis , 2008 .

[223]  Honglei Chen,et al.  Peripheral inflammatory biomarkers and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[224]  E. Lazartigues,et al.  Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.